The company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged.
Latest AC Immune SA news
We have not published a story on AC Immune SA yet. When there is news, it will appear here.
Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents CHF 26.8 million.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about AC Immune SA
What is the ticker symbol of AC Immune SA?
AC Immune SA trades under the ticker ACIU on NASDAQ.
Where is AC Immune SA listed?
AC Immune SA is listed on NASDAQ. Our directory also records these other listings: DUS:IMR; FWB:IMR; GETTEX:IMR; HAM:IMR; HAN:IMR; LS:A2AR5F; MUN:IMR; SWB:IMR; TRADEGATE:IMR; XETR:IMR.
What is the SEC CIK of AC Immune SA?
The SEC Central Index Key (CIK) for AC Immune SA is 1651625. Its filings are on SEC EDGAR.
How many shares does AC Immune SA have outstanding?
101,742,231 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-13.
Which country or territory is AC Immune SA listed under?
Our directory records AC Immune SA under Switzerland.
What does AC Immune SA do?
Our directory classifies AC Immune SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of AC Immune SA?
The ISIN recorded for AC Immune SA is CH0329023102.
Does aibio.space cover AC Immune SA?
aibio.space lists AC Immune SA among 2,820 public biotech companies and publishes its news here as stories appear.
Where is AC Immune SA incorporated?
SEC records list its state or country of incorporation as V8.
What is the latest AC Immune SA (ACIU) stock news?
Our latest story on AC Immune SA, dated Sep 4, 2025: "AC Immune to cut about 30% of workforce, sees CHF 127.1 million lasting to Q3 2027". The company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged. Source.
How long will AC Immune SA's cash last?
From our story of Sep 4, 2025: The Swiss company, which develops treatments and diagnostics for Alzheimer's and Parkinson's diseases, says the move sharpens its focus and pushes its cash runway to the end of the third quarter of 2027. Source.
Is AC Immune SA in financial distress?
Our latest distress story, dated Sep 4, 2025: "AC Immune to cut about 30% of workforce, sees CHF 127.1 million lasting to Q3 2027". The company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged. Source.
Is AC Immune SA a smaller reporting company?
SEC records list AC Immune SA's filer category as: Accelerated filer.
Where is AC Immune SA headquartered?
SEC records list its business address as EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, Switzerland, 00000.
When does AC Immune SA's fiscal year end?
AC Immune SA's fiscal year ends on December 31, per SEC records.
Investor discussion: AC Immune SA
Members talk about AC Immune SA (ACIU). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at AC Immune SA, newest first. Each line links the filing it comes from.
Distress
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ACIU on TradingView.
SEC filings and registration
SEC name
AC Immune SA
CIK
1651625
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ACIU (Nasdaq)
State or country of incorporation
V8
Fiscal year ends
December 31
Filer category
Accelerated filer
Business address
EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, Switzerland, 00000
Phone
41 21 345 91 21
Shares outstanding
101,742,231 as of 2025-12-31 (20-F filed 2026-03-13)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
AC Immune SA is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACIU, recorded under Switzerland. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio